CMIC Establishes "AI Basic Policy" Based on Practical Knowledge

CMIC Co., Ltd. (Headquarters: Minato-ku, Tokyo; President and CEO: Shunji Katayama; hereinafter referred to as CMIC) announces that it has established an "AI Basic Policy" to promote the responsible utilization of AI technology.

CMIC has been developing internal guidelines for AI utilization, implementing education and training for appropriate AI use, and progressively introducing AI tools. Furthermore, with a view to advancing its business operations, CMIC has also embarked on advanced initiatives, including the strategic introduction of agent-type AI. This basic policy, based on the knowledge accumulated through these practical experiences, aims to articulate common values and decision-making principles across the entire company, thereby deepening AI utilization and establishing governance simultaneously.

Background

AI technology is rapidly spreading as a tool to improve operational efficiency and sophistication. On the other hand, new challenges such as information security, privacy, ethics, and bias have also emerged.

As a CRO supporting the development and post-marketing activities of pharmaceuticals and medical devices, CMIC operates in a business that demands high quality and reliability. Moreover, to advance clients' pharmaceutical development and post-marketing operations swiftly and reliably, and to deliver value to patients faster, CMIC is promoting aggressive AI utilization as a management policy. Therefore, considering the characteristics of its business, CMIC believes that risk management and governance assurance in AI utilization are indispensable.

Based on this recognition, CMIC has been progressively deepening its understanding of AI utilization and building an operational foundation since an early stage. This basic policy has now been established to integrate these efforts and present them clearly externally.

Past Initiatives

CMIC has been promoting the following initiatives across the group since 2023 for the application of AI in business operations:

<Establishment of Governance Foundation>

- June 2023: Formulation and implementation of guidelines for the use of generative AI

- December 2023: CMIC Solutions Co., Ltd. ICT Division led the launch of an AI utilization course, promoting company-wide improvement of AI literacy

<Introduction of Tools for Operational Efficiency and Expansion of Utilization>

- October 2023: Internal ChatGPT introduced

- November 2023: Recruitment of test users for Microsoft 365 Copilot began, and verification in actual business operations commenced

- February 2024: Microsoft 365 Copilot rolled out to all employees, promoting its utilization in daily operations

<Advanced AI Utilization for Business Sophistication at CMIC>

- December 2025: Strategic business partnership established with Bluenote, a US-based provider of AI platforms specialized for life sciences. Further promotion of initiatives for regulatory document creation support and advanced quality control using agent-type AI.

In addition, CMIC has been promoting the use of AI in various business areas, such as document creation support, information organization, and streamlining internal communication, within each department, accumulating use cases. Furthermore, through these initiatives, an environment has been established where all employees can utilize AI in their daily operations.

These initiatives have been progressively promoted with careful verification and appropriate controls, based on the high quality and reliability required for pharmaceutical development support.

Positioning of the AI Basic Policy

This basic policy is positioned as the highest guideline for AI utilization at CMIC, indicating the direction of AI utilization in conjunction with existing AI guidelines and various internal regulations.

CMIC aims to contribute to the advancement of healthcare and medicine by improving productivity and creating new value through the utilization of AI in the healthcare field.

This policy consists of the following six principles, demonstrating the fundamental concepts for responsible AI utilization:

- Human-centricity and Safety

- Fairness

- Governance and Accountability

- Data Protection and Security

- Legal Compliance and Intellectual Property

- Human Resource Development and Literacy

Future Initiatives

CMIC has been promoting the adoption of appropriate AI utilization tailored to business characteristics through the sharing of internal use cases and education/awareness campaigns.

Based on this basic policy, CMIC will promote the further expansion of advanced technologies, including agent-type AI, and the strengthening of the supporting governance system in an integrated manner. CMIC will also continuously review operational rules and governance systems in light of social demands and technological trends.

CMIC will continue to promote the utilization of digital technologies, including AI, while ensuring transparency and ethicality in areas requiring quality and reliability, thereby realizing faster and higher value-added pharmaceutical development support.

Full Text of the AI Basic Policy

https://www.cmicgroup.com/corporate/group-companies/files/pdf/CMICAI2607.pdf

About CMIC Co., Ltd.

As one of Japan's largest CROs (Contract Research Organizations), CMIC Co., Ltd. provides integrated support from the development to post-marketing phases of pharmaceuticals and medical devices. It offers a wide range of services, including development strategy consulting, clinical development (monitoring, data management, statistical analysis, safety management), regulatory affairs support, and post-marketing surveillance (PMS), all on a one-stop basis.

Leveraging its extensive development track record, domestic and international network, and digital technology utilization, CMIC achieves development support that balances efficiency and quality. It addresses the drug lag issue facing Japan and contributes to improving access to medical care. For more details, please visit our website.

URL: https://www.cmicgroup.com/corporate/group-companies/cmic/